Insmed Rises 0.71% as Volume Ranks 224th Post-FDA Approval Price Target Hiked to 240

On August 13, 2025, Insmed (INSM) closed with a 0.71% gain, while its trading volume of $530 million ranked 224th in the equity market, reflecting a 38.44% decline from the previous day’s activity.

H.C. Wainwright upgraded its price target for Insmed to $240 from $120, maintaining a "Buy" rating following the FDA’s approval of Brinsupri for non-cystic fibrosis bronchiectasis (NCFB). The firm highlighted the drug’s potential to expand into chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS) by 2027 and 2028, respectively. Analysts noted Brinsupri’s unique position as the first and only FDA-approved oral treatment for NCFB, with clinical trials showing significant reductions in exacerbation rates compared to placebo.

Investor sentiment surged on Stocktwits, with retail traders shifting to "extremely bullish" sentiment amid high message volume. The revised price target implies a 97% upside from the prior close, reinforcing confidence in Insmed’s pipeline diversification and market differentiation in neutrophil-mediated disease treatments.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.